The medical cannabis industry is one of the biggest potential new markets, attracting growing interest from the business community and the public. It is also attracting significant attention of the regulators, most notably the MHRA, the FSA and the Home Office in the UK. The law and regulation in the UK of medical cannabis and the sale of cannabidiol (CBD) is complex, often contradictory and rapidly developing. There are also different regulatory regimes applying to medical cannabis and CBD products sold to consumers.
We are seen as go-to specialists on the regulatory and investment landscape affecting medical cannabis and CBD products and are currently advising a number of companies in the space. We also work with academic institutions and non-profits, tailoring legal solutions aligned with their institutional needs and risk preferences.
The team, comprised of specialists in regulatory, corporate, commercial and IP, as well as a team of brand specialists in MDR Brand Management, supports both domestic and international businesses and individuals at every level of the medicinal cannabis supply chain, on all aspects related to this fast changing and entrepreneurial sector.
At the core of the practice are life sciences specialists with scientific and technical backgrounds providing regulatory guidance relevant to conducting business and investing in medicinal cannabis and CBD. We have advised clients in relation to the regulatory requirements in the UK, most notably from the DFLU of the Home Office, the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Food Safety Agency. We have liaised with the Advisory Council in the Misuse of Drugs, the All Party Parliamentary Group on medicinal cannabis and the MHRA borderline products unit to both make submissions and to influence outcomes.